The global Vernal Keratoconjunctivitis Market is expected to garner a market value of USD 436.9 Million in 2023 and is expected to accumulate a market value of USD 782.42 Million by registering a CAGR of 6% in the forecast period 2023 to 2033.
One of the reasons driving the global market over the projection period is the rising incidence of conjunctivitis in emerging nations. The market for Vernal Keratoconjunctivitis registered a CAGR of 4% in the historical period 2017 to 2022.
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 436.9 Million |
| Anticipated Forecast Value (2033) | USD 782.42 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
According to market research and competitive intelligence provider Future Market Insights- the market for Vernal Keratoconjunctivitis reflected a value of 4% during the historical period, 2017 to 2022.
According to the NCBI article published in August 2021, conjunctivitis can manifest in COVID-19-infected people. Thus, the increasing prevalence of conjunctivitis during the pandemic had the potential to drive the demand for the market.
However, the relaxation of strict lockdowns started to contribute to the increase in the patient inflow for vernal keratoconjunctivitis treatment, adding to the growth of the market. Thus, the market for Vernal Keratoconjunctivitis is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increasing incidence of Vernal Keratoconjunctivitis disease to push the market growth
The increasing prevalence of Vernal Keratoconjunctivitis disease is one of the biggest drivers of the market. As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years.
Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe.
With the increasing prevalence and awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens.
Treatment for vernal keratoconjunctivitis includes oral or over-the-counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available quickly and are found to relieve acute conjunctivitis. Hence, this segment is expected to witness steady growth during the forecast period.
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Vernal Keratoconjunctivitis, less awareness of Vernal Keratoconjunctivitis disease, and insubstantial treatment options are hampering the market growth.
The global conjunctivitis market is anticipated to be constrained by factors such as low illness awareness and inadequate pharmaceutical coverage in developing nations.
Improvement in healthcare spending propelling the growth of Vernal Keratoconjunctivitis in Asia Pacific
The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period.
The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of ocular allergies in the region. Conjunctivitis is quite prevalent in nations like India.
For instance, the state of Tamil Nadu reported a viral conjunctivitis issue among students and workers at schools. Clinical Epidemiology and Global Health, for instance, estimated that 12.22% of Indians suffer from ocular allergies.
The male segment is projected to have a higher prevalence (13.44%) than females (10.71%). During the projected period, these trends are anticipated to support market expansion in the region.
In addition to these factors, an increase in the frequency of infections, poor hygienic conditions in developing nations, and protracted deliveries in several of the region's countries, the Asia Pacific region is anticipated to have the third-largest share. In addition, it is anticipated that the expanding medical tourism sector in nations like Malaysia, China, and India would increase demand for treatment.
Over the anticipated time, these factors will boost market expansion in the region.
High prevalence of ophthalmic allergies shaping the landscape for Vernal Keratoconjunctivitis in North America
North America is anticipated to acquire a market share of about 20% in the forecast period. This growth is attributable to the increasing awareness of ophthalmic allergies. This, coupled with the existence of majority players, which leads to novel and advanced drug launches, and the robust spread of this disease, are factors attributing to the market's growth.
A country like the United States has a major presence of positive reimbursement policies, and this is the key reason for this region's dominance in this market.
As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.
Such prevalence of conjunctivitis in the United States is pushing the demand for an effective treatment, thereby contributing to the market's growth during the forecast period.
The superior efficiency of tablet consumption bolsters the growth
On the basis of treatment, the segment has been divided into gel, ointment, tablets, and others. The tablets are widely used by patients suffering from vernal keratoconjunctivitis which is further triggering the market growth.
Owing to an increased usage of these tablets in the treatment, as they help in the faster recovery of the disease, players are focussing on launching new and sophisticated products.
Key start-up players in the Vernal Keratoconjunctivitis market are-
Key players in the Vernal Keratoconjunctivitis market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 436.9 Million |
| Market Value in 2033 | USD 782.42 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, Drug type, Dosage Form, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Argentina, Germany, The UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, GCC, South Africa |
| Key Companies Profiled | Allakos; iCo Therapeutics; Akari Therapeutics; and Santen |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Dosage Form, 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Dosage Form, 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Dosage Form, 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 18: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Dosage Form, 2018 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: Asia Pacific Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 23: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 24: Asia Pacific Market Value (US$ Million) Forecast by Dosage Form, 2018 to 2033
Table 25: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Dosage Form, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Dosage Form, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Dosage Form, 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Dosage Form, 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Dosage Form, 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 21: Global Market Attractiveness by Drug Type, 2023 to 2033
Figure 22: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 23: Global Market Attractiveness by Dosage Form, 2023 to 2033
Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Dosage Form, 2023 to 2033
Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Dosage Form, 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Dosage Form, 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Dosage Form, 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 46: North America Market Attractiveness by Drug Type, 2023 to 2033
Figure 47: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 48: North America Market Attractiveness by Dosage Form, 2023 to 2033
Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Dosage Form, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Dosage Form, 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Dosage Form, 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Dosage Form, 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Drug Type, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Dosage Form, 2023 to 2033
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 78: Europe Market Value (US$ Million) by Dosage Form, 2023 to 2033
Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 87: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 90: Europe Market Value (US$ Million) Analysis by Dosage Form, 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Dosage Form, 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Dosage Form, 2023 to 2033
Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 96: Europe Market Attractiveness by Drug Type, 2023 to 2033
Figure 97: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 98: Europe Market Attractiveness by Dosage Form, 2023 to 2033
Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: Asia Pacific Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 102: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 103: Asia Pacific Market Value (US$ Million) by Dosage Form, 2023 to 2033
Figure 104: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 105: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: Asia Pacific Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 110: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 111: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 112: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 113: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 114: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 115: Asia Pacific Market Value (US$ Million) Analysis by Dosage Form, 2018 to 2033
Figure 116: Asia Pacific Market Value Share (%) and BPS Analysis by Dosage Form, 2023 to 2033
Figure 117: Asia Pacific Market Y-o-Y Growth (%) Projections by Dosage Form, 2023 to 2033
Figure 118: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 119: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 120: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 121: Asia Pacific Market Attractiveness by Drug Type, 2023 to 2033
Figure 122: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 123: Asia Pacific Market Attractiveness by Dosage Form, 2023 to 2033
Figure 124: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 125: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 126: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 127: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) by Dosage Form, 2023 to 2033
Figure 129: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 130: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 137: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 138: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 139: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 140: MEA Market Value (US$ Million) Analysis by Dosage Form, 2018 to 2033
Figure 141: MEA Market Value Share (%) and BPS Analysis by Dosage Form, 2023 to 2033
Figure 142: MEA Market Y-o-Y Growth (%) Projections by Dosage Form, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 144: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 145: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 146: MEA Market Attractiveness by Drug Type, 2023 to 2033
Figure 147: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 148: MEA Market Attractiveness by Dosage Form, 2023 to 2033
Figure 149: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 150: MEA Market Attractiveness by Country, 2023 to 2033
From 2017 to 2022, the Vernal Keratoconjunctivitis market grew at a CAGR of 4%.
The global Vernal Keratoconjunctivitis market is expected to grow with a 6% CAGR from 2023 to 2033.
As of 2033, the Vernal Keratoconjunctivitis market is expected to reach USD 782.42 Million
According to the FMI analysis, Hospital pharmacies account for the largest market share.
Tablets are expected to show the highest CAGR owing to the increasing demand for new approaches.
North America is expected to possess a 20% market share for the Vernal Keratoconjunctivitis market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
Explore Similar Insights
Vernal Keratoconjunctivitis Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
